您的位置：首页 > 产品中心 > VCaP Cell Line human
VCaP Cell Line human
产品价格
| 产品编号 | 包装单位 | 单价(元) | 国内现货 | 国外库存 | 询价单 |
| 4077158 | 20μl | 4470 | 2-5天 | 4-6周 | |
| 4077158 | 5μg | 4630 | 2-5天 | 4-6周 | |
| 4077158 | 5μg | 5400 | 2-5天 | 4-6周 | |
| 4077158 | 1VL | 11270 | 2-5天 | 4-6周 |
产品性质
| biological source【生物来源】 | human prostate (metastasis) |
| growth mode【生长模式】 | Adherent |
| karyotype【核型】 | Refer to reference (Korenchuk et al., 2001) |
| morphology【形态学】 | Epithelial |
| products【产品】 | Not specified |
| receptors【受体】 | Androgen receptor |
| technique(s) | cell culture | mammalian: suitable |
| relevant disease(s)【相关疾病】 | metastasis |
| shipped in【运输】 | dry ice |
| storage temp.【储存温度】 | −196℃ |
基本信息
| Cell Line Origin【细胞系来源】 | Human Prostate Cancer Metastasis |
| Cell Line Description【细胞系描述】 | This Vertebral-Cancer of the Prostate (VCaP) cell line was established from prostate cancer tissue harvested from a metastatic lesion to a lumbar vertebral body of a patient with hormone refractory prostate cancer. The cells are reported to express large quantities of prostate specific antigen (PSA). This cell line also expresses prostatic acid phosphatase (PAP), cytokeratin-18 and the androgen receptor, and is androgen sensitive in vitro and in vivo. This cell line offers a cell-based model system of human prostate cancer. The cells are tumourigenic in SCID mice. |
| DNA Profile【DNA图谱分析】 | STR-PCR Data: Amelogenin: X,Y CSF1PO: 10,12 D13S317: 11,12 D16S539: 9 D5S818: 12 D7S820: 9,12 THO1: 9.3 TPOX: 8,11 vWA: 18,19 |
| Culture Medium【培养基】 | DMEM:Ham′s F12 (1:1) + 2mM Glutamine + 10% Foetal Bovine Serum (FBS). |
| Subculture Routine【传代培养常规】 | Split sub-confluent cultures (70-80%) 1:2 i.e. seeding at 2-5x10,000 cells/cm2 using 0.25% trypsin; 5% CO2; 37℃. Pellet cells by centrifugation and remove trypsin after inactivation of trypsin at each subculture. |
| Other Notes【其他说明】 | Additional freight & handling charges may be applicable for Asia-Pacific shipments. Please check with your local Customer Service representative for more information. |
